LRRC37A17P: A Potential Drug Target and Biomarker (G644397)

Target Name: LRRC37A17P

NCBI ID: G644397

LRRC37A17P

Other Name(s): LRRC37A5 | Leucine rich repeat containing 37, member A17, pseudogene | leucine rich repeat containing 37 member A17, pseudogene

LRRC37A17P: A Potential Drug Target and Biomarker

LRRC37A17P is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the long non-coding RNA (lncRNA) family, which includes around 1,000 known lncRNAs. LRRC37A17P has been identified as a potential drug target or biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

The LRRC37A17P protein is composed of 219 amino acid residues and has a calculated molecular weight of 23.9 kDa. It is expressed in a variety of tissues, including the brain, heart, and kidneys, and has been shown to be involved in several physiological processes.

One of the most promising aspects of LRRC37A17P is its potential as a drug target. LRRC37A17P has been shown to play a role in several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its role in these diseases is not well understood, but its potential as a drug target makes it an attractive target for researchers to investigate.

LRRC37A17P has been shown to be involved in the regulation of several cellular processes, including cell adhesion, migration, and survival. It has been shown to play a role in the development and progression of cancer, by promoting the growth and survival of cancer cells. LRRC37A17P has also been shown to be involved in the development of neurodegenerative diseases, by contributing to the destruction of dendrites and axons in the brain.

In addition to its potential role in disease, LRRC37A17P has also been shown to be a potential biomarker for several diseases. Its expression has been shown to be associated with several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. This suggests that LRRC37A17P may be a useful biomarker for these diseases, and could potentially be used as a diagnostic tool.

LRRC37A17P is also a good candidate as a drug target because of its small size and the ease of its purification. This makes it easier to study its properties and its potential as a drug. LRRC37A17P has also been shown to have a high degree of homogeneity, which is important for the development of reliable drug candidates.

In conclusion, LRRC37A17P is a protein that has been identified as a potential drug target or biomarker for several diseases. Its properties and its role in several physiological processes make it an attractive target for researchers to investigate. Further studies are needed to fully understand its potential as a drug target and its potential as a biomarker.

Protein Name: Leucine Rich Repeat Containing 37 Member A17, Pseudogene

The "LRRC37A17P Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LRRC37A17P comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets